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Identity 
Other names: AOE37-2, PRX-4 




Prdx4 gene is ubiquitously expressed in various strata 
of life in which more than 40 species has been 
sequenced. 
Description 
Human PRDX4 gene is located on X chromosome at 
p22 location. 
Transcription 
Transcription of PRDX4 gene generates 5 different 
transcripts and the length of the longest is 1005 bp 





Human PRDX4 gene encodes 271 amino acids. It may 
present in biological system as dimeric and decameric 
state. The presence of dimeric or decameric state of 
Prx-4 may be redox regulated (Wood et al., 2002).  
The crystal structure of the decameric Prx-4 has been 
resolved. It is also noteworthy that Prx-4 forms 
heterodimer or multimer with other Prx isoforms. 
Description 
Peroxiredoxin 4 is an antioxidant enzyme that belongs 
to the peroxiredoxin family. The peroxiredoxin family 
of proteins scavenges hydrogen peroxide and plays a 
critical role in cellular response to oxidative stre s and 
intracellular signal transduction. 
Expression 
Peroxiredoxin 4 is abundantly expressed in pancreas, 
liver and heart.  
 
 
Map of X-chromosome showing location of PRDX4 gene. 
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Crystal structure of human peroxiredoxin 4 (PDB 2PN8). 
 
Localisation 
Prx-4 is mainly localized in the endoplasmic reticulum 
(ER), but is also present in the cytosol, lysosome, 
nucleus, or secreted (Leyens et al., 2003). 
Function 
The antioxidant property of Prx-4 may play an essential 
role in the redox balance in the ER. The Cysteine 
residue of Prx-4 is first oxidized to sulfenic acid form 
and then forms intermolecular disulfide bond with 
another Prx molecule, which can be reversed by the 
reducing activity of the thioredoxin-thioredoxin 
reductase system. Under oxidative stress conditions, 
however, the Cysteine of Prx-4 undergoes further 
oxidation to sulfinic/sulfonic acid forms which can 
only be reduced by sulfiredoxin (Jeong et al., 2012). 
The hyperoxidized (or overoxidized) form of Prx-4 
loses its antioxidant property but may function as 
molecular chaperone to facilitate protein folding (Rhee 
and Woo, 2011; Zito et al., 2010). The Prx-4 has also 
been shown to mediate multiple cell signaling 
pathways including the phosphorylation of p38α, 
JNK1/JNK2, GSK3α/GSK3β, MEK1/MEK2, 
MSK1/MSK2, AMPKα, HSP27, Src, Fyn, etc. 
Homology 
As in other typical 2-Cys peroxiredoxins, Prdx4 also 
contains a peroxidatic Cysteine and a resolving 
Cysteine that is separated by 121 amino acids. The 
overall sequence homology of Prx-4 with other 2-Cys 
Prx is at least 56% or higher. In particular, sequences 
surrounding both cysteine residues are highly 
conserved which may indicate the importance of those 




Prx-4 along with sulfiredoxin plays very important role 
in tumor progression and metastasis in lung cancer. The 
expression of Prx-4 is at least 1.5 fold higher in tumor 
cells compared to control and this finding applies most 
frequently to adenocarcinoma and to little bit modestly 
to squamous cell carcinoma (Lehtonen et al., 2004). 
Alteration in expression of Prx-4 results in alteraion in 
rate of tumor progression and metastasis which is 
indicated by anchorage independent colony formation, 
cell migration and invasion of human lung cancer cells 
(Wei et al., 2011). This ability of Prx-4 to promote 
tumor progression and metastasis is supposed to be due 
to its antioxidant properties. Same study has also 
shown role of Srx-Prx-4 axis in activation of 
intracellular phosphokinase signaling including AP-
1/MMP-9 axis and MAPK signaling. 
Leukemia 
Note 
Alteration of Prx-4 expression is proposed to play a 
role in development of different types of leukemia. In 
acute myeloid leukemia (AML) patients, the PRDX4 
gene is fused with the AML1 gene between exon 5 and 
6 of AML1 and exon 2 of Prdx4 (Zhang et al., 2004). 
This fusion of AML1 gene with the Prdx4 gene is  
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supposed to play a role in altered expression of Prdx 4 
in acute myeloid leukemia. In another study, 
researchers have found that the alteration in genomic 
sequence and expression level of Prdx4 is rare in acute 
myeloid leukemia but have found strong reduction in 
Prdx4 expression in acute promyelocytic leukemia 
(APL) (Palande et al., 2011). This study has suggested 
that due to alteration in Prdx4 expression, the signal 
transduction from a myeloid growth factor receptor i.e. 
the granulocyte colony stimulating factor receptor is 
affected. This study have also found the role of histone 
methylation in transcriptional silencing of Prdx4 in
APL. 
Glioblastoma multiforme (GBM) 
Note 
Prx-4 is supposed to play a role in most aggressive 
primary brain malignancy i.e. glioblastoma multiforme 
(Kim et al., 2012). Kim TH et al. have found in this 
study that the knockdown of Prx-4 results in reduce 
cell growth and radiation resistance along with increase 
ROS level, DNA damage and apoptosis in in-vitro 
models. This study suggests the importance of Prx-4 in 
radiation resistance and tumor maintenance of GBM. It 
also proposes the Prx-4 as an important therapeutic 
target in this disorder which can be persuaded for drug 
discovery and may result in development of some anti-
GBM chemotherapeutic drug in future. 
Oral cavity squamous cell carcinoma 
(OSCC) 
Note 
Prx-4 is also studied for its role in tumor progression, 
cell migration and invasiveness in oral cavity squamous 
cell carcinoma (Chang et al., 2011). This study 
proposes that the Prx-4 can act as a good tumor 
prognostic factor as it is highly overexpressed in 
OSCC. Along with the prognostic value of Prx-4 
suggested in paper, the Prx-4 can also be a good 
therapeutic target in OSCC by virtue of its ability to 
mediate cell migration and/or metastasis. The attribu es 
of Prx-4 leading to OSCC should at least be partially 
due its ability to manage oxidative stress. 
Cardiovascular diseases 
Note 
Oxidative stress is considered to play major role in the 
pathological remodeling of arterial wall (Martin-
Ventura et al., 2012). As it is an antioxidant protein, the 
Prx-4 expression level increases in variety of oxidative 
stress conditions. Also, Prx-4 is secreted into 
extracellular environment; therefore, its plasma 
concentration may be used as a molecular indicator of 
various cardiovascular disease and other disorders 
involving oxidative stress. The increased serum  
Prx-4 concentration is considered as a good indicator of 
risk to cardiovascular disease (Abbasi et al., 2012) 
because cardiovascular disease have higher level of 




Prx-4 has the ability to act as a hepato-protective 
protein due to its ability to act as an antioxidant protein, 
by virtue of which Prx-4 can protect the hepatic tissue 
against the Hydrogen peroxide as well as other reactive 
oxygen species causing oxidative stress. A study in rat 
model of Wilson's disease has demonstrated that this 
disease have lower level of Prx-4 expression as 
compared to normal (Ito et al., 2012). The same study 
has proposed that Prx-4 can be used as a potential 
biomarker of hepatic diseases as the Prx-4 serum 
concentration in this model was found to be quite low. 
Non-canonical scurvy 
Note 
Genomic loss of Prx-4 in mice results in testicular 
atrophy due to elevated spermatogenic cell death (Iuchi 
et al., 2009).  
Depletion of Prx-4 along with ER specific thiol 
oxidases ERO1α and ERO1β lead to non-canonical 
scurvy in mice (Zito et al., 2012), which suggests that 
Prx-4 and other ER thiol oxidases may be critical for 
protein folding and disulfide bond formation in the ER. 
In this sense, Prx-4 may also be considered as an 
alternative to ERO1α and ERO1β in higher organisms 
(Zito et al., 2010). 
Inflammatory disease 
Note 
Prx-4 is a secretory antioxidant protein which can be 
detected in plasma.  
By virtue of its antioxidant activity, the extracellular 
Prx-4 can protect the vascular tissue against reactive 
oxygen species and hence, it has ability to inhibit the 
oxidative stress induced inflammation in various tis ues 
and it can also reduce the chances of oxidative stres  
induced diabetes mellitus in animal models (Yamada et 
al., 2012). 
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